Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai-400076, India.
Analyst. 2018 Apr 16;143(8):1916-1923. doi: 10.1039/c8an00224j.
Meningiomas represent one of the most frequently reported non-glial, primary brain and central nervous system (CNS) tumors. Meningiomas often display a spectrum of anomalous locations and morphological attributes, deterring their timely diagnosis. Majority of them are sporadic in nature and thus the present-day screening strategies, including radiological investigations, often result in misdiagnosis due to their aberrant and equivocal radiological facets. Therefore, it is pertinent to explore less invasive and patient-friendly biofluids such as serum for their screening and diagnostics. The utility of serum Raman spectroscopy in diagnosis and therapeutic monitoring of cancers has been reported in the literature. In the present study, for the first time, to the best of our knowledge, we have explored Raman spectroscopy to classify the sera of meningioma and control subjects. For this exploration, 35 samples each of meningioma and control subjects were accrued and the spectra revealed variance in the levels of DNA, proteins, lipids, amino acids and β-carotene, i.e., a relatively higher protein, DNA and lipid content in meningioma. Subsequent Principal Component Analysis (PCA) and Principal Component-Linear Discriminant Analysis (PC-LDA) followed by Leave-One-Out Cross-Validation (LOOCV) and limited independent test data, in a patient-wise approach, yielded a classification efficiency of 92% and 80% for healthy and meningioma, respectively. Additionally, in the analogous analysis between healthy and different grades of meningioma, similar results were obtained. These results indicate the potential of Raman spectroscopy in differentiating meningioma. As present methods suffer from known limitations, with the prospective validation on a larger cohort, serum Raman spectroscopy could be an adjuvant/alternative approach in the clinical management of meningioma.
脑膜瘤是最常见的非神经胶质、原发性脑和中枢神经系统 (CNS) 肿瘤之一。脑膜瘤常表现出一系列异常位置和形态特征，使其难以及时诊断。它们中的大多数是散发性的，因此目前的筛查策略，包括影像学检查，由于其异常和模棱两可的影像学特征，往往导致误诊。因此，探索更具侵袭性和患者友好的生物流体，如血清，进行筛查和诊断是很有必要的。血清拉曼光谱在癌症的诊断和治疗监测中的应用在文献中有报道。在本研究中，据我们所知，这是首次探索拉曼光谱来对脑膜瘤和对照患者的血清进行分类。为此，我们分别收集了 35 例脑膜瘤和对照患者的血清样本，发现它们的光谱在 DNA、蛋白质、脂质、氨基酸和 β-胡萝卜素的水平上存在差异，即脑膜瘤中的蛋白质、DNA 和脂质含量相对较高。随后的主成分分析 (PCA) 和主成分-线性判别分析 (PC-LDA) 以及留一法交叉验证 (LOOCV) 和有限的独立测试数据，采用患者个体方法，健康和脑膜瘤的分类效率分别为 92%和 80%。此外，在健康和不同级别脑膜瘤之间的类似分析中，也得到了类似的结果。这些结果表明拉曼光谱在区分脑膜瘤方面具有潜力。由于目前的方法存在已知的局限性，通过对更大队列的前瞻性验证，血清拉曼光谱可能成为脑膜瘤临床管理的辅助/替代方法。
